Ebola Virus Disease - correlates of protection, determinants of outcome, and clinical management
In response to the Ebola epidemic in West Africa, a H2020 EU research initiative ‘EVIDENT’ was launched in November 2014. EVIDENT provides a research platform which builds upon the success of the European Mobile Laboratory consortium (EMLab) that is performing Ebola Virus Disease (EVD) diagnostics in affected West African countries since March 2014. EVIDENT’s mandate is to scientifically exploit specimens from EVD patients collected as part of the outbreak response in Guinea, Sierra Leone and Nigeria and to gather critical knowledge on B and T cell immunology, biomarkers, virus evolution, virulence determinants, and transmission of Ebola Virus.
- Prof. Stephan GüntherBernhard-Nocht-Institute for Tropical MedicinePhone: +49 40 42818-930Email
- Horizon 2020 & sub-programmes
- 24 months (November 2014 - October 2016)
- Project funding
- € 1,759,325.25
- Project partners